Pfizer on familiar ground as drug price war re-emerges

Fairly or not – and perhaps partly to do with the fact that it is simply the biggest and best-known big pharma company – Pfizer (NYSE: PFE) is normally one of the first to get hit when the US media and public hit out at the drug industry over the price of its products.

The US company came bottom of an analysis from the research consulting firm Reputation Institute,  published by Business Insider last month, that rated pharma companies on their reputation.

Considering the general public's perception of product, prices and public hospitality, the study put Pfizer at the bottom, with the report citing its use of a charity to mask a heart drug price hike